Info: Read More
  • 中药标准品生产商,产品定制服务
  • 血根碱

    Sanguinarine

    血根碱
    产品编号 CFN98259
    CAS编号 2447-54-3
    分子式 = 分子量 C20H14NO4 = 332.3
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Alkaloids
    植物来源 The herbs of Chelidonium majus
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    血根碱 CFN98259 2447-54-3 10mg QQ客服:2159513211
    血根碱 CFN98259 2447-54-3 20mg QQ客服:2159513211
    血根碱 CFN98259 2447-54-3 50mg QQ客服:2159513211
    血根碱 CFN98259 2447-54-3 100mg QQ客服:2159513211
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Universidade Federal de Santa Catarina (Brazil)
  • University of South Australia (Australia)
  • Colorado State University (USA)
  • Charles University in Prague (Czech Republic)
  • Griffith University (Australia)
  • Fraunhofer-Institut für Molekularbiologie und Angewandte ?kologie IME (Germany)
  • Osmania University (India)
  • University of Liège (Belgium)
  • Worcester Polytechnic Institute (USA)
  • Agricultural Research Organization (ARO) (Israel)
  • National Cancer Institute (USA)
  • Copenhagen University (Denmark)
  • Medizinische Universit?t Wien (Austria)
  • Mahatma Gandhi University (India)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • J of Dentistry & Oral Health2019, 2641-1962
  • Molecules.2022, 27(19):6681.
  • Mol Med Rep.2022, 26(4):299.
  • Sci Rep.2015, 5:13194
  • Molecules.2022, 27(22):7887.
  • Srinagarind Medical Journal2019, 34(1)
  • Biosci. Rep.2020, 10.1024
  • Front Immunol.2018, 9:2091
  • Metabolites2022, 12(6),507.
  • Plant Biotechnology Reports 2021, 15:117-124.
  • Int J Immunopathol Pharmacol.2019, 33:2058738419857537
  • Nat Prod Sci.2016, 22(2)
  • J Cell Biochem.2022, 123(7):1222-1236.
  • In Vitro Cellular & Developmental Biology - Plant2022, 58:972-988.
  • Food Research International2023, 113792.
  • Pharmacological Reports2020, 1-9
  • RSC Adv.2018, 32621-32636
  • Int Immunopharmacol. 2020, 83:106403.
  • Journal of Apicultural Research2021, 60(1)
  • ACS Nano.2018, 12(4):3385-3396
  • Agronomy2020, 10(3),388.
  • British Jou. Med.&Med. Research2014, 1802-1811
  • Int J Mol Sci.2023, 24(3):2102.
  • ...
  • 生物活性
    Description: Sanguinarine possesses anticancer, antimicrobial, anti-inflammatory, and antioxidant properties, it has therapeutic potential in preventing the neurodegenerative diseases, it may be used to develop a potential therapeutic drug for treating cardiac remodeling and heart failure and shows protective effects on teeth and alveolar bone health. Sanguinarine can inhibit osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways, and can protect against cardiac hypertrophy and fibrosis via inhibiting NF-κB activation.
    Targets: Akt | NF-kB | ROS | Bcl-2/Bax | Caspase | HIF | PARP | HO-1 | Nrf2 | ERK | Calcium Channel | ATPase | DNA/RNA Synthesis
    In vitro:
    Clin Cancer Res. 2000 Apr;6(4):1524-8.
    Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells.[Pubmed: 10778985]
    Sanguinarine, derived from the root of Sanguinaria canadendid, has been shown to possess antimicrobial, anti-inflammatory, and antioxidant properties. Here we compared the antiproliferative and apoptotic potential of sanguinarine against human epidermoid carcinoma (A431) cells and normal human epidermal keratinocytes (NHEKs).
    METHODS AND RESULTS:
    Sanguinarine treatment was found to result in a dose-dependent decrease in the viability of A431 cells as well as NHEKs albeit at different levels because sanguinarine-mediated loss of viability occurred at lower doses and was much more pronounced in the A431 carcinoma cells than in the normal keratinocytes. DNA ladder assay demonstrated that compared to vehicle-treated control, sanguinarine treatment of A431 cells resulted in an induction of apoptosis at 1-, 2-, and 5-microM doses. Sanguinarine treatment did not result in the formation of a DNA ladder in NHEKs, even at the very high dose of 10 microM. The induction of apoptosis by sanguinarine was also evident by confocal microscopy after labeling the cells with annexin V. This method also identified necrotic cells, and sanguinarine treatment also resulted in the necrosis of A431 cells. The NHEKs showed exclusively necrotic staining at high doses (2 and 5 microM). We also explored the possibility of cell cycle perturbation by sanguinarine in A431 cells. The DNA cell cycle analysis revealed that sanguinarine treatment did not significantly affect the distribution of cells among the different phases of the cell cycle in A431 cells.
    CONCLUSIONS:
    We suggest that sanguinarine could be developed as an anticancer drug.
    Oncotarget. 2015 Apr 30;6(12):10335-49.
    Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach.[Pubmed: 25929337]
    Pancreatic cancer remains one of the most lethal of all human malignancies with its incidence nearly equaling its mortality rate. Therefore, it's crucial to identify newer mechanism-based agents and targets to effectively manage pancreatic cancer. Plant-derived agents/drugs have historically been useful in cancer therapeutics. Sanguinarine is a plant alkaloid with anti-proliferative effects against cancers, including pancreatic cancer. This study was designed to determine the mechanism of sanguinarine's effects in pancreatic cancer with a hope to obtain useful information to improve the therapeutic options for the management of this neoplasm.
    METHODS AND RESULTS:
    We employed a quantitative proteomics approach to define the mechanism of sanguinarine's effects in human pancreatic cancer cells. Proteins from control and sanguinarine-treated pancreatic cancer cells were digested with trypsin, run by nano-LC/MS/MS, and identified with the help of Swiss-Prot database. Results from replicate injections were processed with the SIEVE software to identify proteins with differential expression. We identified 37 differentially expressed proteins (from a total of 3107), which are known to be involved in variety of cellular processes. Four of these proteins (IL33, CUL5, GPS1 and DUSP4) appear to occupy regulatory nodes in key pathways. Further validation by qRT-PCR and immunoblot analyses demonstrated that the dual specificity phosphatase-4 (DUSP4) was significantly upregulated by sanguinarine in BxPC-3 and MIA PaCa-2 cells. Sanguinarine treatment also caused down-regulation of HIF1α and PCNA, and increased cleavage of PARP and Caspase-7.
    CONCLUSIONS:
    Taken together, sanguinarine appears to have pleotropic effects, as it modulates multiple key signaling pathways, supporting the potential usefulness of sanguinarine against pancreatic cancer.
    Environ Toxicol Pharmacol. 2014 Nov;38(3):701-10.
    Involvement of heme oxygenase-1 in neuroprotection by sanguinarine against glutamate-triggered apoptosis in HT22 neuronal cells.[Pubmed: 25299846]
    Sanguinarine is a natural compound isolated from the roots of Macleaya cordata and M. microcarpa, has been reported to possess several biological activities such as anti-inflammatory and anti-oxidant effects.
    METHODS AND RESULTS:
    In the present study, we demonstrated that sanguinarine markedly induces the expression of HO-1 which leads to a neuroprotective response in mouse hippocampus-derived neuronal HT22 cells from apoptotic cell death induced by glutamate. Sanguinarine significantly attenuated the loss of mitochondrial function and membrane integrity associated with glutamate-induced neurotoxicity. Sanguinarine protected against glutamate-induced neurotoxicity through inhibition of HT22 cell apoptosis. JC-1 staining, which is a well-established measure of mitochondrial damage, was decreased after treatment with sanguinarine in glutamate-challenged HT22cells. In addition, sanguinarine diminished the intracellular accumulation of ROS and Ca(2+). Sanguinarine also induced HO-1, NQO-1 expression via activation of Nrf2. Additionally, we found that si RNA mediated knock-down of Nrf2 or HO-1 significantly inhibited sanguinarine-induced neuroprotective response.
    CONCLUSIONS:
    These findings revealed the therapeutic potential of sanguinarine in preventing the neurodegenerative diseases.
    Oncotarget . 2016 Apr 19;7(16):22355-67.
    Noninvasive bioluminescence imaging of the dynamics of sanguinarine induced apoptosis via activation of reactive oxygen species[Pubmed: 26968950]
    Abstract Most chemotherapeutic drugs exert their anti-tumor effects primarily by triggering a final pathway leading to apoptosis. Noninvasive imaging of apoptotic events in preclinical models would greatly facilitate the development of apoptosis-inducing compounds and evaluation of their therapeutic efficacy. Here we employed a cyclic firefly luciferase (cFluc) reporter to screen potential pro-apoptotic compounds from a number of natural agents. We demonstrated that sanguinarine (SANG) could induce apoptosis in a dose- and time-dependent manner in UM-SCC-22B head and neck cancer cells. Moreover, SANG-induced apoptosis was associated with the generation of reactive oxygen species (ROS) and activation of c-Jun-N-terminal kinase (JNK) and nuclear factor-kappaB (NF-κB) signal pathways. After intravenous administration with SANG in 22B-cFluc xenograft models, a dramatic increase of luminescence signal can be detected as early as 48 h post-treatment, as revealed by longitudinal bioluminescence imaging in vivo. Remarkable apoptotic cells reflected from ex vivo TUNEL staining confirmed the imaging results. Importantly, SANG treatment caused distinct tumor growth retardation in mice compared with the vehicle-treated group. Taken together, our results showed that SANG is a candidate anti-tumor drug and noninvasive imaging of apoptosis using cFluc reporter could provide a valuable tool for drug development and therapeutic efficacy evaluation. Keywords: apoptosis; bioluminescence imaging; luciferase reporter; sanguinarine; therapeutic efficacy.
    In vivo:
    Mol Med Rep. 2014 Jul;10(1):211-6.
    Sanguinarine protects against pressure overload‑induced cardiac remodeling via inhibition of nuclear factor-κB activation.[Pubmed: 24804701]
    Cardiac remodeling is a major determinant of heart failure characterized by cardiac hypertrophy and fibrosis. Sanguinarine exerts widespread pharmacological effects, including antitumor and anti‑inflammatory responses. In the present study, the effect of sanguinarine on cardiac hypertrophy, fibrosis and heart function was determined using the model induced by aortic banding (AB) in mice.
    METHODS AND RESULTS:
    AB surgery and sham surgery were performed on male wild‑type C57 mice, aged 8‑10 weeks, with or without administration of sanguinarine from one week after surgery for an additional seven weeks. Sanguinarine protected against the cardiac hypertrophy, fibrosis and dysfunction induced by AB, as assessed by the heart weight/body weight, lung weight/body weight and heart weight/tibia length ratios, echocardiographic and hemodynamic parameters, histological analysis, and the gene expression levels of hypertrophic and fibrotic markers. The inhibitory effect of sanguinarine on cardiac remodeling was mediated by inhibiting nuclear factor (NF)‑κB signaling pathway activation.
    CONCLUSIONS:
    The findings indicated that sanguinarine protected against cardiac hypertrophy and fibrosis via inhibiting NF‑κB activation. These findings may be used to develop a potential therapeutic drug for treating cardiac remodeling and heart failure.
    Biochem Biophys Res Commun. 2013 Jan 18;430(3):951-6.
    Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways.[Pubmed: 23261473 ]
    Sanguinarine is a natural plant extract that has been supplemented in a number of gingival health products to suppress the growth of dental plaque. However, whether sanguinarine has any effect on teeth and alveolar bone health is still unclear.
    METHODS AND RESULTS:
    In this study, we demonstrated for the first time that sanguinarine could suppress osteoclastic bone resorption and osteoclast formation in a dose-dependent manner. Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos. Further investigation revealed that sanguinarine attenuated RANKL-mediated IκBα phosphorylation and degradation, leading to the impairment of NF-κB signaling pathway during osteoclast differentiation. In addition, sanguinarine also affected the ERK signaling pathway by inhibiting RANKL-induced ERK phosphorylation.
    CONCLUSIONS:
    Collectively, this study suggested that sanguinarine has protective effects on teeth and alveolar bone health.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.0093 mL 15.0466 mL 30.0933 mL 60.1866 mL 75.2332 mL
    5 mM 0.6019 mL 3.0093 mL 6.0187 mL 12.0373 mL 15.0466 mL
    10 mM 0.3009 mL 1.5047 mL 3.0093 mL 6.0187 mL 7.5233 mL
    50 mM 0.0602 mL 0.3009 mL 0.6019 mL 1.2037 mL 1.5047 mL
    100 mM 0.0301 mL 0.1505 mL 0.3009 mL 0.6019 mL 0.7523 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    德卡林碱; Decarine CFN98909 54354-62-0 C19H13NO4 = 319.3 5mg QQ客服:3257982914
    氯化两面针碱; Nitidine chloride CFN98109 13063-04-2 C21H18ClNO4 = 383.83 20mg QQ客服:2159513211
    血根碱; Sanguinarine CFN98259 2447-54-3 C20H14NO4 = 332.3 20mg QQ客服:2159513211
    二氢血根碱; Dihydrosanguinarine CFN92810 3606-45-9 C20H15NO4 = 333.1 20mg QQ客服:1413575084
    6-Methoxydihydrosanguinarine; 6-Methoxydihydrosanguinarine CFN89299 72401-54-8 C21H17NO5 = 363.36 5mg QQ客服:2056216494
    6-乙氧基二氢血根碱; 6-Ethoxydihydrosanguinarine CFN89308 28342-31-6 C22H19NO5 = 377.39 10mg QQ客服:3257982914
    去甲血根碱; Norsanguinarine CFN92811 522-30-5 C19H11NO4 = 317.1 5mg QQ客服:215959384
    氧化血根碱; Oxysanguinarine CFN91002 548-30-1 C20H13NO5 = 347.3 10mg QQ客服:3257982914
    白屈菜红碱; Chelerythrine CFN98449 34316-15-9 C21H18NO4 = 348.4 20mg QQ客服:3257982914
    博落回醇碱; Bocconoline CFN95373 32906-88-0 C22H21NO5 = 379.4 5mg QQ客服:3257982914

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产